Novel metabolic targeted LC-MS/MS assay to differentiate pancreatic cancer from chronic pancreatitis in plasma

Objectives Pancreatic ductal adenocarcinoma (PDAC) is characterized by a poor prognosis with overall 5-year survival rates of less than 6%. In resectable pancreatic cancer cases, the 5-year survival rates increase to 18-24%. Therefore, an early diagnosis is key of a potentially curative treatment, and screening of patients at risk is desirable. Chronic pancreatitis (CP) patients have a 26-fold increased risk for the development of pancreatic cancer. Conventional diagnostic methods such as transabdominal ultrasound and CA19-9 testing suffer from insufficient clinical performance.
Source: Pancreatology - Category: Gastroenterology Authors: Tags: Session 5. Pancreatic Cancer: predispositions and diagnostic advances - free papers Source Type: research